Viking Therapeutics's Options Frenzy: What You Need to Know
Portfolio Pulse from Benzinga Insights
Viking Therapeutics (NASDAQ:VKTX) has seen a mix of bullish and bearish options trading, with a notable volume of trades predicting a price range of $20 to $100 in the next three months. The company, specializing in biopharmaceutical development for metabolic and endocrine disorders, has its stock currently at $78.96, slightly down with an RSI indicating potential overbought status. Analysts, including one from HC Wainwright & Co., have set a target price of $90, despite the mixed sentiment in options trading.
May 08, 2024 | 7:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Viking Therapeutics has seen varied options trading activity, with a current stock price of $78.96 and a target price of $90 by analysts. The company focuses on biopharmaceuticals for metabolic and endocrine disorders.
The mixed options trading sentiment and the current analyst target price suggest a neutral short-term impact on VKTX's stock price. The bearish and bullish trades indicate uncertainty, while the analyst target points to potential upside. However, the RSI hinting at an overbought condition could temper short-term gains.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100